These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34697955)

  • 1. Chemotherapy-induced hearing loss: the applications of bio-nanotechnologies and bile acid-based delivery matrices.
    Foster T; Ionescu C; Walker D; Jones M; Wagle S; Kovacevic B; Brown D; Mikov M; Mooranian A; Al-Salami H
    Ther Deliv; 2021 Oct; 12(10):723-737. PubMed ID: 34697955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bile acid permeation enhancement for inner ear cochlear drug pharmacological uptake: bio-nanotechnologies in chemotherapy-induced hearing loss.
    Carey L; Walker D; Jones M; Ionescu C; Wagle S; Kovacevic B; Brown D; Mikov M; Mooranian A; Al-Salami H
    Ther Deliv; 2021 Dec; 12(12):807-819. PubMed ID: 34761700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Nanoencapsulation Technology and its Potential Role in Bile Acid-Based Targeted Gene Delivery to the Inner Ear.
    Foster T; Lewkowicz M; Quintas C; Ionescu CM; Jones M; Wagle SR; Kovacevic B; Wong EYM; Mooranian A; Al-Salami H
    Small; 2023 Feb; 19(8):e2204986. PubMed ID: 36538754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Review on Recent Advancement on Age-Related Hearing Loss: The Applications of Nanotechnology, Drug Pharmacology, and Biotechnology.
    Chester J; Johnston E; Walker D; Jones M; Ionescu CM; Wagle SR; Kovacevic B; Brown D; Mikov M; Mooranian A; Al-Salami H
    Pharmaceutics; 2021 Jul; 13(7):. PubMed ID: 34371732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss.
    Crabb SJ; Martin K; Abab J; Ratcliffe I; Thornton R; Lineton B; Ellis M; Moody R; Stanton L; Galanopoulou A; Maishman T; Geldart T; Bayne M; Davies J; Lamb C; Popat S; Joffe JK; Nutting C; Chester J; Hartley A; Thomas G; Ottensmeier C; Huddart R; King E
    Eur J Cancer; 2017 Dec; 87():75-83. PubMed ID: 29128692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin and aminoglycoside antibiotics: hearing loss and its prevention.
    Schacht J; Talaska AE; Rybak LP
    Anat Rec (Hoboken); 2012 Nov; 295(11):1837-50. PubMed ID: 23045231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ototoxicity.
    Rybak LP; Ramkumar V
    Kidney Int; 2007 Oct; 72(8):931-5. PubMed ID: 17653135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implantable Drug Reservoir Devices for Inner Ear Delivery of Pharmacotherapeutics.
    Kita A; Saldate J; Chang C; Chellappa N; Jong J; Matsuda R; Schmidt A; Shih B; Shafqat I; Schoettler K; Acharya S; Seidlits S; Hoffman L
    Otolaryngol Head Neck Surg; 2020 Oct; 163(4):791-798. PubMed ID: 32484378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-induced hearing loss.
    Prescrire Int; 2014 Dec; 23(155):290-4. PubMed ID: 25629145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The protective role of ferulic acid against cisplatin-induced ototoxicity.
    Jo ER; Youn CK; Jun Y; Cho SI
    Int J Pediatr Otorhinolaryngol; 2019 May; 120():30-35. PubMed ID: 30753979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer.
    Frisina RD; Wheeler HE; Fossa SD; Kerns SL; Fung C; Sesso HD; Monahan PO; Feldman DR; Hamilton R; Vaughn DJ; Beard CJ; Budnick A; Johnson EM; Ardeshir-Rouhani-Fard S; Einhorn LH; Lipshultz SE; Dolan ME; Travis LB
    J Clin Oncol; 2016 Aug; 34(23):2712-20. PubMed ID: 27354478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Protein arginine methyltransferase 6 reduces reactive oxygen species production and attenuates aminoglycoside- and cisplatin-induced hair cell death.
    He Y; Li W; Zheng Z; Zhao L; Li W; Wang Y; Li H
    Theranostics; 2020; 10(1):133-150. PubMed ID: 31903111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ototoxicity: therapeutic opportunities.
    Rybak LP; Whitworth CA
    Drug Discov Today; 2005 Oct; 10(19):1313-21. PubMed ID: 16214676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin-induced ototoxicity: Updates on molecular mechanisms and otoprotective strategies.
    Tang Q; Wang X; Jin H; Mi Y; Liu L; Dong M; Chen Y; Zou Z
    Eur J Pharm Biopharm; 2021 Jun; 163():60-71. PubMed ID: 33775853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sound preconditioning therapy inhibits ototoxic hearing loss in mice.
    Roy S; Ryals MM; Van den Bruele AB; Fitzgerald TS; Cunningham LL
    J Clin Invest; 2013 Nov; 123(11):4945-9. PubMed ID: 24216513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nicotinamide adenine dinucleotide: An essential factor in preserving hearing in cisplatin-induced ototoxicity.
    Kim HJ; Oh GS; Shen A; Lee SB; Khadka D; Pandit A; Shim H; Yang SH; Cho EY; Song J; Kwak TH; Choe SK; Park R; So HS
    Hear Res; 2015 Aug; 326():30-9. PubMed ID: 25891352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating protective and therapeutic effects of alpha-lipoic acid on cisplatin-induced ototoxicity.
    Kim KH; Lee B; Kim YR; Kim MA; Ryu N; Jung DJ; Kim UK; Baek JI; Lee KY
    Cell Death Dis; 2018 Aug; 9(8):827. PubMed ID: 30068942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanotechnology: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(19):1-43. PubMed ID: 23074489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aminoglycoside- and Cisplatin-Induced Ototoxicity: Mechanisms and Otoprotective Strategies.
    Kros CJ; Steyger PS
    Cold Spring Harb Perspect Med; 2019 Nov; 9(11):. PubMed ID: 30559254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial.
    Freyer DR; Chen L; Krailo MD; Knight K; Villaluna D; Bliss B; Pollock BH; Ramdas J; Lange B; Van Hoff D; VanSoelen ML; Wiernikowski J; Neuwelt EA; Sung L
    Lancet Oncol; 2017 Jan; 18(1):63-74. PubMed ID: 27914822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.